Topical finasteride — prescriber resource

Mechanism of action

Finasteride is a 4-azasteroid, a competitive and specific inhibitor of type II 5α-reductase (the principal isoform in scalp hair follicles, dermal papilla and reproductive tissues). Inhibition reduces the conversion of testosterone to dihydrotestosterone (DHT), the more potent androgen implicated in the pathogenesis of androgenetic alopecia (AGA).²

In male AGA, DHT binds the androgen receptor in dermal papilla cells of frontal and vertex follicles, shortening anagen and progressively reducing follicle diameter. Sustained reduction of local DHT supports recovery of miniaturised follicles and slowing of further loss.²

Pharmacokinetics of the topical formulation

The cutaneous spray solution most extensively studied (P-3074, finasteride 0.25% w/v) was characterised by Caserini et al. in healthy male volunteers.⁴^,⁷ Key features reported in those studies:

• Topical application delivers approximately 100 µg of finasteride per pump activation; recommended dosing involves a small number of pump activations to the affected scalp area once daily.
• Plasma finasteride C_max is markedly lower after topical than oral administration of the 1 mg tablet.
• Scalp DHT is suppressed to a degree comparable to that observed with oral therapy at the level of the follicle.
• Serum DHT reduction is smaller in magnitude than with oral 1 mg, consistent with the lower systemic exposure.

Clinical efficacy

The principal efficacy reference is the phase III non-inferiority trial by Piraccini et al., a 24-week, randomised, double-blind, double-dummy, parallel-group multicentre trial comparing the 0.25% topical finasteride spray with oral finasteride 1 mg/day in men with mild-to-moderate AGA.¹

• Primary endpoint: change from baseline in target-area hair count at week 24. Topical finasteride met the pre-specified non-inferiority margin versus oral.
• Systemic DHT: smaller maximum reduction with topical than oral therapy, consistent with the lower systemic exposure.
• Safety: incidence of treatment-emergent adverse events broadly similar between topical and oral groups in the trial, though numerically lower for some sexual-function-related events with topical therapy. As ever, RCT data should be interpreted alongside real-world signals.

Pooled evidence from systematic review (Lee et al., 2018⁵) and a recent network meta-analysis of nonsurgical AGA therapies (Gupta et al., 2022⁸) is consistent with a meaningful efficacy signal versus placebo and a comparable position to oral therapy in indirect comparisons.

Safety profile

The systemic safety case for topical finasteride rests on its substantially lower plasma exposure compared with oral 1 mg dosing. However, topical delivery does not preclude systemic absorption, and product information for topical preparations carries the same class warnings as the oral product, including:

• Sexual dysfunction (reduced libido, erectile dysfunction, ejaculation disorders).
• Psychiatric reactions including depression and, rarely, suicidal ideation — strengthened in MHRA labelling following the 2023 Drug Safety Update⁶ and in EMA-coordinated EU labelling.⁹
• Breast tenderness or enlargement; rare cases of male breast cancer have been reported in association with finasteride class drugs.
• Hypersensitivity reactions, including local skin reactions specific to topical use.

Reports of persistent symptoms after discontinuation (commonly referred to as post-finasteride syndrome, PFS) remain an active area of post-marketing surveillance and ongoing debate. Clinicians should counsel patients accordingly and document the discussion.

Prescribing considerations

Indication

Treatment of mild-to-moderate androgenetic alopecia in adult men. Not indicated for women of childbearing potential, paediatric patients, or alopecia secondary to other causes.

Contraindications

Hypersensitivity to finasteride or any excipient; pregnancy (Category X for the class; topical handling precautions apply for household contacts).

Cautions

History of mood disorder, sexual dysfunction prior to therapy, breast cancer (personal or family history). PSA monitoring considerations in patients of prostate-screening age — finasteride reduces serum PSA and laboratory results should be adjusted accordingly.

Pregnancy & fertility

Topical finasteride should not be used by, or come into contact with, women who are or may become pregnant due to risk of feminisation of a male fetus. Men planning conception should discuss timing with their prescriber; pausing therapy is commonly advised prior to conception.

Application

Once-daily application to dry, undamaged scalp at the site of thinning, per product information. Wash hands after application; avoid transfer to partners or children.

Concomitant therapy

Frequently combined with topical or oral minoxidil; combination has been shown to outperform either monotherapy in randomised trials.¹⁰

Monitoring and review

Treatment effect is conventionally reviewed at 3, 6 and 12 months using standardised photography and patient-reported outcomes. Persistent absence of response by 12 months should prompt reassessment of diagnosis, adherence, and consideration of combination or alternative therapy. Adverse-event review should be conducted at every contact and patients counselled to seek prompt medical advice for any persistent psychiatric or sexual symptoms.

Reference materials

1. ¹ Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomised, controlled trial. J Eur Acad Dermatol Venereol. 2022;36(2):286-294. PMC9297965
2. ² Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol. 2002;198(1-2):89-95.
3. ³ Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589. JAAD
4. ⁴ Caserini M, Radicioni M, Leuratti C, et al. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. Int J Clin Pharmacol Ther. 2014;52(10):842-849. PubMed
5. ⁵ Lee SW, Juhasz M, Mobasher P, et al. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. J Drugs Dermatol. 2018;17(4):457-463. PubMed
6. ⁶ MHRA Drug Safety Update — finasteride: rare reports of suicidal thoughts and other psychiatric reactions. gov.uk
7. ⁷ Caserini M, Radicioni M, Leuratti C, et al. P-3074: a novel topical formulation of finasteride for the treatment of androgenetic alopecia. Drug Des Devel Ther. 2016. PubMed
8. ⁸ Gupta AK, Bamimore MA, Foley KA. Comparative efficacy and safety of nonsurgical interventions for adults with androgenetic alopecia. JAMA Dermatol. 2022. PubMed
9. ⁹ European Medicines Agency — Article 31 referral on finasteride 1 mg/5 mg medicines. ema.europa.eu
10. ¹⁰ Hu R, Xu F, Han Y, et al. Combined treatment with oral finasteride and topical minoxidil in male androgenetic alopecia: a randomized comparative study. Skinmed. 2015. PubMed

Download a PDF copy of this reference page · Full Research & Evidence library

Expert commentary

For the avoidance of doubt: this page is not promotional material. It is intended as a neutral, evidence-led summary for healthcare professionals making prescribing decisions in their usual practice.